Quick Answer
Cogent Biosciences, Inc. reported Total Assets of $937.61 million for the year ending 2025.
- Cogent Biosciences, Inc. showed an increase of +185.9% in Total Assets from 2024 to 2025.
- This data is from Cogent Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on February 17, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: $43.42 million | Q2 2018: $102.72 million | Q3 2018: $94.79 million | Q1 2019: $81.28 million | Q2 2019: $69.31 million | Q3 2019: $57.88 million | Q1 2020: $38.94 million | Q2 2020: $31.06 million | Q3 2020: $139.87 million | Q1 2021: $237.61 million | Q2 2021: $228.52 million | Q3 2021: $215.39 million | Q1 2022: $206.87 million | Q2 2022: $366.05 million | Q3 2022: $331.56 million | Q1 2023: $263.20 million | Q2 2023: $392.37 million | Q3 2023: $355.45 million | Q1 2024: $476.11 million | Q2 2024: $429.94 million | Q3 2024: $384.02 million | Q1 2025: $283.80 million | Q2 2025: $274.82 million | Q3 2025: $425.93 million.
- Over the full 9 years of available data (2017 to 2025), Cogent Biosciences, Inc.'s Total Assets has grown by 1,809.0%.
- Historical annual values: Fiscal year 2025: $937.61 million | Fiscal year 2024: $327.90 million | Fiscal year 2023: $313.44 million | Fiscal year 2022: $300.81 million | Fiscal year 2021: $232.09 million | Fiscal year 2020: $250.92 million | Fiscal year 2019: $49.42 million | Fiscal year 2018: $85.93 million | Fiscal year 2017: $49.12 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: